Posted in | News | MEMS - NEMS | Nanoenergy

mPhase Technologies to Recommence Federal Funding Efforts for Scalable Smart Reserve Cell Technology

mPhase Technologies, Inc. (OTCBB: XDSL) announced today that it will recommence active efforts in January of 2011 to secure federal funding for its scalable smart reserve cell technology, one of the line items included in the Fiscal Year 2011 Defense Appropriations bill that was passed in the United States House of Representatives.

Scalable Smart Reserve Cell Technology was listed to receive funding as part of the omnibus appropriations bill that failed to achieve a bipartisan compromise in the United States Senate in December of 2010, as part of the budget for the current 2011 fiscal year. Nevertheless, the Company is actively seeking to have such line item funding reintroduced in January of 2011, as part of early consideration in a defense appropriations bill for the 2011 fiscal year, and it is anticipated that it should be a high-priority item for the next Congress to augment to the temporary resolution that is currently funding the U.S. government.

"We are encouraged that the prior Congress has recognized the importance of this technology," said Mr. Ronald Durando, mPhase's President and Chief Executive Officer. The bill that was passed by the House of Representative in the last Congressional session is the first time Congress specifically designated funding for this type of technology. The Company continues to believe that it will be well positioned for a defense appropriations line item in the next Congress that convenes in January of 2011, given the company's leadership in the field.

The company is a leader in developing new innovative products using micro fluid dynamics, MEMS and super-hydrophobic suspension and separation of liquids on micro structures of silicon, developed through the science of nanotechnology. mPhase began using nanotechnology to develop power cells in 2004 with the Bell Labs division of Alcatel-Lucent (formerly Lucent Technologies, Inc.)

The Company has successfully delivered to the United States Army under a Phase II STTR grant a prototype of its Smart NanoBattery. "We believe that the successful delivery of a prototype of a first of its kind reserve battery designed for backup power for critical mission computer memory is vital in strategic weapons systems and sensor networks," said Durando. The company is positioned to custom tailor its Smart NanoBattery for a variety of military subsystems and critical mission commercial products. The Company is in the process of applying for new Phase I grants under both STTR and SBIR programs promulgated by the United States Department of Defense and the United States Department of Energy, as well as National Science Foundation grants.

Source: http://www.mphasetech.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MyPebble. (2019, February 13). mPhase Technologies to Recommence Federal Funding Efforts for Scalable Smart Reserve Cell Technology. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=21098.

  • MLA

    MyPebble. "mPhase Technologies to Recommence Federal Funding Efforts for Scalable Smart Reserve Cell Technology". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=21098>.

  • Chicago

    MyPebble. "mPhase Technologies to Recommence Federal Funding Efforts for Scalable Smart Reserve Cell Technology". AZoNano. https://www.azonano.com/news.aspx?newsID=21098. (accessed November 21, 2024).

  • Harvard

    MyPebble. 2019. mPhase Technologies to Recommence Federal Funding Efforts for Scalable Smart Reserve Cell Technology. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=21098.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.